Bora Pharmaceuticals Co., Ltd. Overview
Pro stress-test →Bora Pharmaceuticals is a premier international pharmaceutical services company dedicated to contributing to better health all over the world. The company employs a distinctive dual-engine strategy integrating scalable, high-quality CDMO growth with innovative drug development focused on specialty pharma and rare diseases.
Strategic Profile
Pro stress-test →Bora is a premier international CDMO specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products, delivering to more than 100 markets around the world. The company operates across Taiwan, the United States, and Canada, with more than 95% of revenue generated outside Taiwan.
Competitive Landscape
Pro stress-test →Bora emerged as a development-scale CDMO and top CNS/neurology product distributor in Taiwan, with Lexapro and Lendormin as key market blockbusters. The company competes in the outsourced pharma manufacturing and specialty drug distribution space alongside other Taiwan-based and international CDMO providers. Global pharma manufacturers increasingly rely on CDMO partners for cost-efficient manufacturing.
Industry Context
Bora Pharmaceuticals Co., Ltd. operates in Pharmaceutical Manufacturing & Contract Development and Manufacturing Organization (CDMO).
Key facts
Founded: 2007 · Headquarters: Taipei, Taiwan · Market cap: $2.37B